Targets › BCL2
28 programs from 23 companies in 360 trials: 203 Phase 2, 122 Phase 1, 32 Phase 3, 3 Phase 4; Oncology, Hematology, Metabolic and endocrine; next expected readout Nov 2026.
Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. (UniProt, P10415)
Open in Phaseline: the race on BCL2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AbbVie | Venetoclax Apoptosis regulator Bcl-2 inhibitor | BCL2 | Phase 4 | Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia; Myelodysplastic Syndrome (MDS); Chronic Lymphocytic Leukemia … | Nov 2026 |
| BeOne Medicines | Sonrotoclax Tablet for Oral Suspension (BGB-11417) Bcl-2 inhibitor | BCL2 | Phase 3 | Mantle Cell Lymphoma; Chronic Lymphocytic Leukemia; CLL; Waldenstrom Macroglobulinemia … | Nov 2026 |
| Ascentage Pharma Group | Apg-2575 Apoptosis regulator Bcl-2 inhibitor | BCL2 | Phase 3 | CLL/SLL; Acute Myeloid Leukemia; Higher-risk Myelodysplastic Syndrome; Chronic Lymphocytic Leukemia … | Dec 2026 |
| AbbVie | Navitoclax Apoptosis regulator Bcl-2 inhibitor; Apoptosis regulator Bcl-X inhibitor; Apoptosis regulator Bcl-W inhibitor | BCL2, BCL2L1, BCL2L2, BCL2L2-PABPN1 | Phase 3 | Myelofibrosis (MF); Myeloproliferative Neoplasm; Mantle Cell Lymphoma Refractory; High Grade Serous Carcinoma … | Dec 2026 |
| Alliance for Clinical Trials in Oncology | Sonrotoclax BCL-2 inhibitor | BCL2 | Phase 3 | Chronic Lymphocytic Leukemia | Sep 2028 |
| Liping Dou | BCL-2 inhibitor (Zemestosita) BCL-2 inhibitor | BCL2 | Phase 2 | R/R AML | Mar 2027 |
| Ruijin Hospital | Sonrotoclax (SON) BCL2 inhibitor | BCL2 | Phase 2 | Acute Myeloid Leukemia | May 2027 |
| The First Affiliated Hospital of Xiamen University | veneclax BCL2 inhibitor | BCL2 | Phase 2 | Acute Myeloid Leukemia | Jun 2027 |
| Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | BCL-2 inhibitors combined with the HyperCVAD regimen BCL-2 inhibitor combined with HyperCVAD (hyperfractionated cyclophosphamide, doxorubicin, | BCL2 | Phase 2 | Lymphoblastic Lymphoma, Adult | Aug 2027 |
| German CLL Study Group | Sonrotoclax BCL-2 inhibitor | BCL2 | Phase 2 | Richter Transformation | Aug 2027 |
| BeiGene | BGB-11417 (sonrotoclax) BCL2 inhibitor | BCL2 | Phase 2 | Leukemia; MCL; Chronic Lymphocytic Leukemia (CLL) | Aug 2027 |
| Shanghai Jiao Tong University School of Medicine | sonrotoclax (BGB11417) BCL2 inhibitor | BCL2 | Phase 2 | Acute Myeloid Leukemia | Oct 2027 |
| Guangzhou Lupeng Pharmaceutical Company | Lacutoclax (LP-108) selective BCL-2 inhibitor | BCL2 | Phase 2 | Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; Acute Myeloid Leukemia | Dec 2027 |
| Peking University People's Hospital | Sonrotoclax BCL-2 inhibitor | BCL2 | Phase 2 | AL Amyloidosis (AL) | Dec 2027 |
| Massachusetts General Hospital | Sonrotoclax (BGB-11417) B-cell lymphoma 2 (BCL2) protein inhibitor | BCL2 | Phase 2 | Chronic Lymphocytic Leukemia | Mar 2028 |
| Fred Hutchinson Cancer Center | Sonrotoclax BCL-2 inhibitor | BCL2 | Phase 2 | Chronic Lymphocytic Leukemia | Aug 2028 |
| Christine Ryan | Sonrotoclax BCL-2 protein inhibitor | BCL2 | Phase 2 | Mantle Cell Lymphoma | Nov 2029 |
| Canadian Cancer Trials Group | Sonrotoclax BCL-2 inhibitor | BCL2 | Phase 2 | Mantle Cell Lymphoma | Dec 2029 |
| Cothera Bioscience | Sepantronium Bromide (PC-002) BCL2 inhibitor | BCL2 | Phase 2 | High-grade B-cell Lymphoma | – |
| Lomond Therapeutics Holdings | Lonitoclax (ZE50-0134) BCL2 inhibitor | BCL2 | Phase 1 | Acute Myeloid Leukemia; CLL / SLL | Dec 2026 |
| National Cancer Institute (NCI) | Pelcitoclax Bcl-2/Bcl-XL inhibitor | BCL2, BCL2L1 | Phase 1 | Advanced Endometrial Carcinoma | Feb 2027 |
| Bio-Path Holdings | BP1002 Bcl-2 antisense oligodeoxynucleotide | BCL2 | Phase 1 | Mantle Cell Lymphoma; Acute Myeloid Leukemia, in Relapse | Mar 2027 |
| BeOne Medicines | BGB-21447 Bcl-2 inhibitor | BCL2 | Phase 1 | Hormone-receptor-positive Breast Cancer | Jul 2027 |
| Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Sonrotoclax BCL-2 inhibitor | BCL2 | Phase 1 | Myelodysplastic Syndromes, High Risk | Dec 2027 |
| Shanghai Fosun Pharmaceutical Industrial Development | FXS0683 BCL-2 inhibitor | BCL2 | Phase 1 | B-Cell Lymphoma | Aug 2028 |
| City of Hope Medical Center | Sonrotoclax B-cell lymphoma-2 (Bcl-2) inhibitor | BCL2 | Phase 1 | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Jan 2029 |
| Ascentage Pharma Group | APG-3288 Dual BCL-2 and MCL-1 inhibitor | BCL2, MCL1, BCL-XL | Phase 1 | Relapsed/Refractory Hematological Malignancies | Dec 2029 |
| Ascentage Pharma Group | APG-1252 BCL-2 family protein inhibitor | BCL2, BCL2L1, BCL2L2, MCL1 | Phase 1 | EGFR Positive Non-small Cell Lung Cancer | – |
Acute Myeloid Leukemia (73) Chronic Lymphocytic Leukemia (34) Mantle Cell Lymphoma (11) Chronic Lymphocytic Leukemia (CLL) (9) Acute Myeloid Leukemia (AML) (8) AML (7) Waldenstrom Macroglobulinemia (6) Leukemia (6) T-cell Acute Lymphoblastic Leukemia (5) Myelodysplastic Syndromes (5) CLL/SLL (5) Multiple Myeloma (4)
small molecule (20), mixed (8)
Ascentage Pharma Group (3) Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (2) AbbVie (2) BeOne Medicines (2) Peking University People's Hospital (1) Bio-Path Holdings (1) Liping Dou (1) City of Hope Medical Center (1) Shanghai Jiao Tong University School of Medicine (1) BeiGene (1) Shanghai Fosun Pharmaceutical Industrial Development (1) Ruijin Hospital (1) Fred Hutchinson Cancer Center (1) National Cancer Institute (NCI) (1) The First Affiliated Hospital of Xiamen University (1) Massachusetts General Hospital (1) German CLL Study Group (1) Alliance for Clinical Trials in Oncology (1) Lomond Therapeutics Holdings (1) Guangzhou Lupeng Pharmaceutical Company (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.